Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
07 Novembre 2024 - 10:05PM
Business Wire
- Presentations to be webcast on
www.exelixis.com -
Exelixis, Inc. (Nasdaq: EXEL) today announced that company
management will participate in fireside chats at the following
investor conferences in November:
- Guggenheim’s Inaugural Healthcare Innovation Conference:
Exelixis is scheduled to present at 9:00 a.m. ET / 6:00 a.m. PT on
Tuesday, November 12 in Boston.
- Stifel 2024 Healthcare Conference: Exelixis is scheduled to
present at 10:20 a.m. ET / 7:20 a.m. PT on Monday, November 18 in
New York City.
- Jefferies London Healthcare Conference: Exelixis is scheduled
to present at 10:30 a.m. BST / 5:30 a.m. ET / 2:30 a.m. PT on
Tuesday, November 19 in London, UK.
To access the webcast links, log onto www.exelixis.com and
proceed to the Event Calendar page under the Investors & News
heading. Replays will also be available at the same location for at
least 30 days.
About Exelixis
Exelixis is a globally ambitious oncology company innovating
next-generation medicines and regimens at the forefront of cancer
care. Powered by drug discovery and development excellence, we are
rapidly evolving our product portfolio to target an expanding range
of tumor types and indications with our clinically differentiated
pipeline of small molecules, antibody-drug conjugates and other
biotherapeutics. This comprehensive approach harnesses decades of
robust investment in our science and partnerships to advance our
investigational programs and extend the impact of our flagship
commercial product, CABOMETYX® (cabozantinib). Exelixis is driven
by a bold scientific pursuit to create transformational treatments
that give more patients hope for the future. For information about
the company and its mission to help cancer patients recover
stronger and live longer, visit www.exelixis.com, follow
@ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and
follow Exelixis on LinkedIn.
Exelixis, the Exelixis logo and CABOMETYX are
registered U.S. trademarks.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241107742591/en/
Investors Contact: Varant Shirvanian Director, Investor
Relations Exelixis, Inc. 650-837-7917 vshirvanian@exelixis.com
Media Contact: Hal Mackins For Exelixis, Inc.
415-994-0040 hal@torchcommunications.com
Grafico Azioni Exelixis (NASDAQ:EXEL)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Exelixis (NASDAQ:EXEL)
Storico
Da Gen 2024 a Gen 2025
